IMM 124E

Drug Profile

IMM 124E

Alternative Names: Anti-LPS colostrum (Imm124-E) - Immuron; Bovine colostrum - Immuron; IMM-124E; IMM122-I

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immuron
  • Developer Emory University; Hadassah Medical Organization; Immuron; La Trobe University; University of Melbourne; University of Zurich; Virginia Commonwealth University
  • Class Antibodies; Hepatoprotectants; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alcoholic hepatitis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Preclinical Autistic disorder; Gastroenteritis
  • No development reported Metabolic syndrome

Most Recent Events

  • 07 Mar 2018 Topline efficacy and pharmacokinetics data from a phase II trial in Non-alcoholic steatohepatitis released by Immuron
  • 21 Nov 2017 Immuron has patent protection for IMM 124E Non-alcoholic steatohepatitis in Australia before November 2017
  • 15 Nov 2017 Immuron receives patent allowance for IMM 124E for Non-alcoholic steatohepatitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top